Merck, Inc.
🇺🇸United States
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
Phase 3
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 559
- Registration Number
- NCT02775435
Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)
Phase 2
Terminated
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT02759315
A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)
Phase 1
Completed
- Conditions
- Gram-Positive Bacterial Infections
- Interventions
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02750761
Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)
Phase 3
Completed
- Conditions
- Sleep Initiation and Maintenance DisordersAlzheimer Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 285
- Registration Number
- NCT02750306
Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
Phase 3
Completed
- Conditions
- Intra-abdominal InfectionComplicated Intra-abdominal Infection
- Interventions
- Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT02739997
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 746
- Registration Number
- NCT02738879
Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT02731742
Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)
Phase 3
Completed
- Conditions
- Urinary Tract Infection (UTI)Complicated Urinary Tract InfectionUncomplicated PyelonephritisPyelonephritis
- Interventions
- Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 115
- Registration Number
- NCT02728089
Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: MK-1029 150 mgDrug: MK-1029 Matching-image PlaceboDrug: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2018-09-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 142
- Registration Number
- NCT02720081
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 481
- Registration Number
- NCT02720068
© Copyright 2025. All Rights Reserved by MedPath